Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets ...

Market Domination host Josh Lipton and guest host, Bullseye American Ingenuity Fund Portfolio Manager Adam Johnson, focus in ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Year-to-date, both Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) delivered negative stock performance ... of Disease Study BMI Collaborators analysis published in The Lancet this March ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

(Reuters) -As Denmark’s Novo Nordisk (NYSE:NVO) shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

After years of researching the finance industry, Simons realized the untapped potential of employing quantitative analysis ... on the stock. During a call with an analyst, Novo Nordisk stated ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

Our analysis is essentially based on how sell-side ... between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Novo Nordisk is expected to post ...

Our analysis is essentially based ... in earnings estimate revisions and short-term stock price movements. For the current quarter, Novo Nordisk is expected to post earnings of $0.91 per share ...

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings, but cuts its guidance for the year. For the full year, the company now expects sales growth ...